Genetic Influences in Breast Cancer Drug Resistance

Adhitiya Daniyal,1 Ivana Santoso,1 Nadira Hasna Putri Gunawan,1 Melisa Intan Barliana,2,3 Rizky Abdulah1,2 1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Indonesia; 2Center of Excellence in Higher Education for Pharmaceutical Care Innovat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daniyal A, Santoso I, Gunawan NHP, Barliana MI, Abdulah R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	breast cancer genetic polymorphisms resistance therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ae258ae209c54dc28b8954044802883a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ae258ae209c54dc28b8954044802883a
record_format	dspace
spelling	oai:doaj.org-article:ae258ae209c54dc28b8954044802883a2021-12-02T13:30:40ZGenetic Influences in Breast Cancer Drug Resistance1179-1314https://doaj.org/article/ae258ae209c54dc28b8954044802883a2021-02-01T00:00:00Zhttps://www.dovepress.com/genetic-influences-in-breast-cancer-drug-resistance-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Adhitiya Daniyal,1 Ivana Santoso,1 Nadira Hasna Putri Gunawan,1 Melisa Intan Barliana,2,3 Rizky Abdulah1,2 1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Indonesia; 2Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Jatinangor, Indonesia; 3Department of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, IndonesiaCorrespondence: Melisa Intan BarlianaDepartment of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung Sumedang KM. 21, Jatinangor, 45363, IndonesiaTel +622284288812Fax +62-22-84288896Email melisa.barliana@unpad.ac.idAbstract: Breast cancer is the most common cancer in adult women aged 20 to 50 years. The therapeutic regimens that are commonly recommended to treat breast cancer are human epidermal growth factor receptor 2 (HER2) targeted therapy, endocrine therapy, and systemic chemotherapy. The selection of pharmacotherapy is based on the characteristics of the tumor and its hormone receptor status, specifically, the presence of HER2, progesterone receptors, and estrogen receptors. Breast cancer pharmacotherapy often gives different results in various populations, which may cause therapeutic failure. Different types of congenital drug resistance in individuals can cause this. Genetic polymorphism is a factor in the occurrence of congenital drug resistance. This review explores the relationship between genetic polymorphisms and resistance to breast cancer therapy. It considers studies published from 2010 to 2020 concerning the relationship of genetic polymorphisms and breast cancer therapy. Several gene polymorphisms are found to be related to longer overall survival, worse relapse-free survival, higher pathological complete response, and increased disease-free survival in breast cancer patients. The presence of these gene polymorphisms can be considered in the treatment of breast cancer in order to shape personalized therapy to yield better results.Keywords: breast cancer, genetic polymorphisms, resistance therapyDaniyal ASantoso IGunawan NHPBarliana MIAbdulah RDove Medical Pressarticlebreast cancergenetic polymorphismsresistance therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 13, Pp 59-85 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer genetic polymorphisms resistance therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	breast cancer genetic polymorphisms resistance therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Daniyal A Santoso I Gunawan NHP Barliana MI Abdulah R Genetic Influences in Breast Cancer Drug Resistance
description	Adhitiya Daniyal,1 Ivana Santoso,1 Nadira Hasna Putri Gunawan,1 Melisa Intan Barliana,2,3 Rizky Abdulah1,2 1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Indonesia; 2Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Jatinangor, Indonesia; 3Department of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, IndonesiaCorrespondence: Melisa Intan BarlianaDepartment of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung Sumedang KM. 21, Jatinangor, 45363, IndonesiaTel +622284288812Fax +62-22-84288896Email melisa.barliana@unpad.ac.idAbstract: Breast cancer is the most common cancer in adult women aged 20 to 50 years. The therapeutic regimens that are commonly recommended to treat breast cancer are human epidermal growth factor receptor 2 (HER2) targeted therapy, endocrine therapy, and systemic chemotherapy. The selection of pharmacotherapy is based on the characteristics of the tumor and its hormone receptor status, specifically, the presence of HER2, progesterone receptors, and estrogen receptors. Breast cancer pharmacotherapy often gives different results in various populations, which may cause therapeutic failure. Different types of congenital drug resistance in individuals can cause this. Genetic polymorphism is a factor in the occurrence of congenital drug resistance. This review explores the relationship between genetic polymorphisms and resistance to breast cancer therapy. It considers studies published from 2010 to 2020 concerning the relationship of genetic polymorphisms and breast cancer therapy. Several gene polymorphisms are found to be related to longer overall survival, worse relapse-free survival, higher pathological complete response, and increased disease-free survival in breast cancer patients. The presence of these gene polymorphisms can be considered in the treatment of breast cancer in order to shape personalized therapy to yield better results.Keywords: breast cancer, genetic polymorphisms, resistance therapy
format	article
author	Daniyal A Santoso I Gunawan NHP Barliana MI Abdulah R
author_facet	Daniyal A Santoso I Gunawan NHP Barliana MI Abdulah R
author_sort	Daniyal A
title	Genetic Influences in Breast Cancer Drug Resistance
title_short	Genetic Influences in Breast Cancer Drug Resistance
title_full	Genetic Influences in Breast Cancer Drug Resistance
title_fullStr	Genetic Influences in Breast Cancer Drug Resistance
title_full_unstemmed	Genetic Influences in Breast Cancer Drug Resistance
title_sort	genetic influences in breast cancer drug resistance
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/ae258ae209c54dc28b8954044802883a
work_keys_str_mv	AT daniyala geneticinfluencesinbreastcancerdrugresistance AT santosoi geneticinfluencesinbreastcancerdrugresistance AT gunawannhp geneticinfluencesinbreastcancerdrugresistance AT barlianami geneticinfluencesinbreastcancerdrugresistance AT abdulahr geneticinfluencesinbreastcancerdrugresistance
_version_	1718392935395885056

Genetic Influences in Breast Cancer Drug Resistance

Ejemplares similares